» TMC278 Demonstrates Long-Term Efficacy And Tolerability In Treatment-Naïve Adults With HIV
New phase IIb data from Tibotec Pharmaceuticals Ltd. show that TMC278, the company’s once-daily, investigational non-nucleoside reverse transcriptase inhibitor (NNRTI), provides long-term efficacy…